Project Grant R03CA292975
Award Date
9/19/24
Completion Date
8/31/26
Dollars Obligated
$171K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Arlington, TX 76019, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), will fund a $334,233 research project conducted by the University of South Carolina. The project aims to examine disparities in the use of novel cancer therapies, as well as the impacts of comorbidities and multilevel factors on treatment outcomes and survival trajectories for lung and colon cancer patients, particularly among minority and rural...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $357,694 to conduct research on health insurance coverage and disparities in cancer outcomes. The primary awardee is the University of Colorado-Denver, which will link data from the Colorado Central Cancer Registry and Colorado All-Payer Claims Database to analyze the impact of health plan type, patient demographics, market factors, and...
This $477,869 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop tailored, multilevel cervical cancer interventions for ethnically diverse Black women. The primary awardee, the University of Texas at Arlington, will work to (1) identify multilevel determinants of routine cervical cancer screening and follow-up adherence among African American women and Black African immigrant women, (2) co-design intervention components to promote...
This Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $2,951,369 to the University of Texas Health Science Center at Houston (UTHealth) to implement and evaluate a primary care-based cancer survivorship care delivery intervention at 8 community health centers in Texas. The key products and services to be delivered under this 5-year award include: (1) implementing a system-level cancer survivorship...
The National Cancer Institute (NCI) awarded a $200,000 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The grant, awarded on September 15, 2023, supports research to develop novel therapeutic approaches to remediate radiotherapy-induced bone necrosis in oropharyngeal cancer patients, particularly among African-American populations who...
The National Cancer Institute (NCI) awarded a $2,447,812 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program to The University of Texas MD Anderson Cancer Center. This five-year grant (Sep 2024 - Aug 2029) will fund research to maintain and enrich the MD Anderson Oropharynx (MDA-OPC) Cohort, an active, single-institution, prospective longitudinal cancer research cohort. The research will focus on three integrated projects to study and mitigate delayed...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $402,600 to the Fred Hutchinson Cancer Center in Seattle, Washington to conduct research on disparities in financial and clinical outcomes among commercially-insured cancer patients following the implementation of the Affordable Care Act (ACA). The key objectives of this 4-year study are to: 1) Understand how the characteristics of...
The National Cancer Institute (NCI) awarded a 5-year, $183,708 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Virginia Commonwealth University (VCU) to elucidate the role of the vaginal microbiome in racial disparities of precancerous cervical lesions. The project aims to measure changes in the vaginal microbiome, psychological stress, and cortisol response among 75 Black and 75 White women diagnosed with cervical lesions. The research seeks to understand how racial...
The federal Project Grant award R01CA281885 in the amount of $656,014 was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The grant is funding a randomized clinical trial of a telemedicine-mHealth symptom cluster intervention for advanced cancer patients in underserved rural communities. The intervention, called "Finding Our Center Under Stress (FOCUS)", is a 4-module mHealth program that teaches patients...
The National Cancer Institute (NCI) awarded a $168,500 Project Grant under the "Cancer Cause and Prevention Research" (CFDA 93.393) program to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The two-year grant, with an ultimate completion date of July 31, 2025, aims to evaluate physical and mental health symptoms (patient-reported outcomes) throughout the cancer diagnosis trajectory and their associations with cancer outcomes among HIV-positive...